GlassScriptPhysician profile
Kathleen Doherty
NPI 1629776125
$2,107.04
in general payments reported to CMS, 2019-2025
25 companies · $1,700 in 2025
The $1,700 reported for 2025 was more than what 94% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $407 · 2025: $1,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,107.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $316.05 | 2024-2025 | |
| Novo Nordisk INC | $279.94 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $225.99 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $212.17 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $128.84 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $102.15 | 2024-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $77.57 | 2024-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $71.30 | 2025 | Rexulti |
| Pfizer INC. | $70.54 | 2025 | |
| Radius Health, INC. | $55.58 | 2024-2025 | Tymlos |
| Phathom Pharmaceuticals, INC. | $53.35 | 2025 | Voquezna |
| Tandem Diabetes Care, INC. | $52.69 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kowa Pharmaceuticals America, INC. | $52.46 | 2024-2025 | Zoryve |
| Exact Sciences Corporation | $51.80 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $47.03 | 2025 | Gemtesa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $47.00 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $39.70 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $36.68 | 2025 | Zenpep |
| Verona Pharma, INC. | $36.41 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.85 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $34.29 | 2024-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.14 | 2024-2025 | Xifaxan |
| Dexcom, INC. | $22.05 | 2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $16.13 | 2025 | Auvelity |
| Soleno Therapeutics, INC. | $14.33 | 2025 | Vykat Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Doherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.